Becton Dickinson and Co (BDX) : Alerus Financial Na added new position in Becton Dickinson and Co during the most recent quarter end. The investment management firm now holds 26,590 shares of Becton Dickinson and Co which is valued at $4,626,128 , the company said in a statement filed on Aug 11, 2016 with the SEC.Becton Dickinson and Co makes up approximately 0.75% of Alerus Financial Na’s portfolio.
Other Hedge Funds, Including , Bluemountain Capital Management added BDX to its portfolio by purchasing 7,293 company shares during the most recent quarter which is valued at $1,268,836. Becton Dickinson and Co makes up approx 0.04% of Bluemountain Capital Management’s portfolio.Fiduciary Group boosted its stake in BDX in the latest quarter, The investment management firm added 639 additional shares and now holds a total of 23,104 shares of Becton Dickinson and Co which is valued at $4,019,634. Becton Dickinson and Co makes up approx 1.08% of Fiduciary Group’s portfolio.Reliance Trust Co Of Delaware reduced its stake in BDX by selling 372 shares or 3.74% in the most recent quarter. The Hedge Fund company now holds 9,570 shares of BDX which is valued at $1,664,989. Becton Dickinson and Co makes up approx 0.15% of Reliance Trust Co Of Delaware’s portfolio.Boston Partners boosted its stake in BDX in the latest quarter, The investment management firm added 98,459 additional shares and now holds a total of 934,685 shares of Becton Dickinson and Co which is valued at $162,382,825. Becton Dickinson and Co makes up approx 0.22% of Boston Partners’s portfolio.
Becton Dickinson and Co opened for trading at $174.75 and hit $176 on the upside on Tuesday, eventually ending the session at $174.91, with a gain of 0.26% or 0.45 points. The heightened volatility saw the trading volume jump to 6,88,449 shares. Company has a market cap of $37,243 M.
On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Investors should note that on Jul 26, 2016, Becton Dickinson and Co announced a cash dividend of $0.6600. The company’s management has announced Sep 7, 2016 as the ex-dividend date and fixed the record date on Sep 9, 2016. The payable date has been fixed on Sep 30, 2016.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.